Indegene Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Indegene Ltd filed with BSE on 06 May 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Indegene reported Q4 FY26 revenue crossing ₹1,000 crores for the first time and full-year FY26 revenue of ₹35,105 million, up 23.6% year-on-year in INR terms and 18.2% in USD terms. Full year adjusted EBITDA was ₹6,793 million, up 20.8% year-on-year, while reported PAT declined 1.4% to ₹4,011 million due to a one-time provision for a US class action lawsuit settlement. Management described several large new deal wins including a Tectonic omnichannel engagement in Germany with its largest customer and a multiyear omnichannel deal exceeding $10 million in ACV.
Numbers mentioned
Q4 Revenue: about ₹10,000 million (Q4 FY26)
p. 9
“Quarter 4 revenue came in about ₹10,000 million, the first quarter in Indegene's history to cross this threshold, growing 6.5% quarter-on-quarter and a strong 32.8% year-over-year.”
Suhas Prabhu, page 9 of the filed PDF · View the filing
Full year revenue: ₹35,105 million (FY26)
p. 9
“For the full year, the revenue was ₹35,105 million, reflecting a 23.6% growth in INR terms and 18.2% in USD terms, ahead of FY25 on both measures.”
Suhas Prabhu, page 9 of the filed PDF · View the filing
Adjusted EBITDA: ₹6,793 million (FY26)
p. 9
“The full year adjusted EBITDA totalled ₹6,793 million, up 20.8% yearon-year.”
Suhas Prabhu, page 9 of the filed PDF · View the filing
Q4 Adjusted EBITDA: ₹1,889 million (Q4 FY26)
p. 9
“Our Q4 adjusted EBITDA came in at ₹1,889 million, growing 23.2% year-over-year.”
Suhas Prabhu, page 9 of the filed PDF · View the filing
Reported EBITDA (Q4): ₹1,648 million (Q4 FY26)
p. 9
“Considering this charge, the reported EBITDA would be lower at ₹1,648 million.”
Suhas Prabhu, page 9 of the filed PDF · View the filing
Q4 PAT: ₹797 million (Q4 FY26)
p. 9
“Hence, the Q4 PAT came in at ₹797 million and the full year PAT of ₹4,011 million, a 1.4% decline.”
Suhas Prabhu, page 9 of the filed PDF · View the filing
Adjusted PAT: ₹4,583 million (FY26)
p. 9
“Excluding these non-operational onetime expenses and factoring retroactive adoption of the cash flow hedge accounting from the start year, PAT would be higher at ₹4,583 million, growing 12.7% year-on-year.”
Suhas Prabhu, page 9 of the filed PDF · View the filing
Provision for lawsuit settlement: ₹203 million (Q4 FY26)
p. 9
“Further, we have provided ₹203 million towards the estimated cost of settling the U.S. class action lawsuit filed in 2020 alleging breach of TCPA.”
Suhas Prabhu, page 9 of the filed PDF · View the filing
Operating cash flow: ₹6,508 million (FY26)
p. 10
“Operating cash flows were ₹6,508 million versus ₹4,419 million in the prior year, which is a 162% ratio on PAT.”
Suhas Prabhu, page 10 of the filed PDF · View the filing
Free cash flow: ₹6,065 million (FY26)
p. 10
“Free cash flows were a strong ₹6,065 million versus ₹4,119 million in the past year.”
Suhas Prabhu, page 10 of the filed PDF · View the filing
Cash and investment position: approximately ₹15,385 million (FY26 year-end)
p. 10
“We closed FY26 with a cash and investment position of approximately ₹15,385 million, just ₹1,258 million lower than FY25 despite ₹7,253 million of outflows towards the acquisitions that we made during the year.”
Suhas Prabhu, page 10 of the filed PDF · View the filing
Final dividend: ₹2.25 per equity share (FY26)
p. 10
“we have proposed a final dividend of ₹2.25 per equity share for FY26.”
Suhas Prabhu, page 10 of the filed PDF · View the filing
DSO: 63 days (FY26)
p. 10
“This is, of course, higher due to the higher non-cash expenses and amortization charges, but also an improvement in the DSOs to 63 days from 72 days in the past year.”
Suhas Prabhu, page 10 of the filed PDF · View the filing
Revenue per employee: approximately USD75,000 per annum (FY26)
p. 4
“The tangible proof of our ability to leverage AI is visible in our industry-leading revenue per employee, now at approximately USD75,000 per annum, up from USD56,000, 3 years back.”
Manish Gupta, page 4 of the filed PDF · View the filing
Top 20 customer revenue: ₹25,200 million (FY26)
p. 4
“Across the top 20 as a group, revenue grew from ₹22,082 million to ₹25,200 million in FY26, steady, compounding expansion driven by portfolio breadth and recurring engagements.”
Manish Gupta, page 4 of the filed PDF · View the filing
Active customer base: 91 (FY26)
p. 4
“Our total active customer base grew from 73 to 91 during the year.”
Manish Gupta, page 4 of the filed PDF · View the filing
Customers over $1 million annual revenue: 53 (FY26)
p. 4
“The number of customers contributing more than $1 million in annual revenue grew from 41 to 53, an approx. 30% increase.”
Manish Gupta, page 4 of the filed PDF · View the filing
North America revenue mix: 71.6% (FY26)
p. 10
“Our geographical mix remains stable with North America at 71.6%, Europe at 25.5% and the Rest of the World at 2.9%, with North America contribution increasing marginally by approximately 2% due to BioPharm, which is entirely a U.S. focused business.”
Suhas Prabhu, page 10 of the filed PDF · View the filing
Organic constant currency growth: 12% (Q4 FY26 YoY)
p. 16
“Constant currency terms year-on-year growth has been 12% organic and a little north of 3% QoQ.”
Suhas Prabhu, page 16 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
EBITDA margin recovery — earlier levels of higher margins · second half of FY27
stated conditionally by Suhas Prabhu
p. 11
“With the growth momentum, we believe that we are on track to improve our profitability and EBITDA margins in FY27 and the second half of FY27 will see us revert to the earlier levels of higher margins with these investments getting fully absorbed and delivering growth.”
Suhas Prabhu, page 11 of the filed PDF · View the filing
PAT — FY27
stated conditionally by Suhas Prabhu
p. 11
“Further, we will also see a positive impact of the interest income with high cash balance and stable yields. Amortization stabilizing and coming off towards the latter half of FY27 and the impact of the one-off and exceptional items fading away, we believe that PAT in FY27 will see a significant upward movement.”
Suhas Prabhu, page 11 of the filed PDF · View the filing
Tectonic revenue contribution — material growth driver for enterprise commercial · FY27
stated as an aspiration by Manish Gupta
p. 8
“Crucially, the Q4 win in Germany with our largest customers provides strong momentum heading into FY27 with additional markets are actively in conversation, Tectonic is on track to become a material growth driver for enterprise commercial in FY27.”
Manish Gupta, page 8 of the filed PDF · View the filing
Largest customer engagement — first $50 million-plus customer · FY27
stated as an aspiration by Manish Gupta
p. 4
“And FY27 is where we expect it to convert into visible growth and we are hoping this customer is going to cross over and become our first $50 million-plus customer.”
Manish Gupta, page 4 of the filed PDF · View the filing
Revenue guidance — FY27
stated firmly by Manish Gupta
p. 11
“I want to be direct, we're not providing formal revenue guidance.”
Manish Gupta, page 11 of the filed PDF · View the filing
Debtor days — mid-60s to 70 days
stated as an aspiration by Suhas Prabhu
p. 13
“But having said that, I would guide towards mid-60s to 70 days on a steady basis.”
Suhas Prabhu, page 13 of the filed PDF · View the filing
EBITDA margin range
stated firmly by Manish Gupta
p. 14
“Maintaining this broad range is very doable as we see it today.”
Manish Gupta, page 14 of the filed PDF · View the filing
BioPharm synergies — FY27
stated conditionally by Suhas Prabhu
p. 16
“But as we speak, we are also looking at synergies on the data subscriptions, on the business operations, and eventually go-to-market. And we would progressively start impacting us through the quarters in FY27 more positively.”
Suhas Prabhu, page 16 of the filed PDF · View the filing
$10 million deal revenue recognition — FY27
stated firmly by Suhas Prabhu
p. 15
“From a revenue recognition perspective, it is deferred because this is an outcome-based pricing model and will be entirely recognized in FY27.”
Suhas Prabhu, page 15 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management attributed RPE growth to sustained productivity gains and outcome-based pricing, and said the $10 million+ cohort is stable as some clients take longer to change operating models.
Answered by Suhas Prabhu
Asked by Prakash Kapadia: Why has revenue per employee increased and is the $10 million+ client cohort growing?
p. 13
“So, there is a sustained effort to increase this in combination with the technology impacting our operations positively, combined with the outcome or output-based pricing model in our engagement, which help us retain the benefits of the productivity increase without being dependent on timesheet-based or input prices.”
Suhas Prabhu, page 13 of the filed PDF · View the filing
Management guided towards mid-60s to 70 days on a steady basis.
Answered by Suhas Prabhu
Asked by Prakash Kapadia: Will debtor days remain stable going forward?
p. 13
“So, debtors have reduced significantly, resulting in higher cash flows. And we are seeing a trend reducing from mid-80s about 5 years ago to the 60s as we speak.”
Suhas Prabhu, page 13 of the filed PDF · View the filing
Management said domain expertise combined with proprietary data and multiple integrated AI models is defensible in the medium term, as LLMs alone lack reliability for regulated, operating-grade work.
Answered by Manish Gupta
Asked by Prolin Nandu: How defensible is the domain-knowledge moat against commoditization by large LLMs?
p. 14
“So at least in the medium term, call it 3 to 5 years, we don't see LLMs having the ability to do this. LLMs still don't have the reliability when you're talking about in operating grade.”
Manish Gupta, page 14 of the filed PDF · View the filing
Management acknowledged ongoing R&D and go-to-market investments but said any margin expansion beyond the target range would be reinvested rather than expected to grow further.
Answered by Manish Gupta
Asked by Prolin Nandu: What is the risk that continued AI investment does not deliver the expected margin recovery?
p. 14
“And one reason why we're not saying that our margins will expand beyond what they used to be, while there might be leverage over there, is because we believe that anything above that range we are operating in, we are going to reinvest in the business.”
Manish Gupta, page 14 of the filed PDF · View the filing
Management explained Cortex is a knowledge engineering platform for building agentic workflows combining multiple frontier models, computer vision, and large action models with a decoupled domain layer.
Answered by Manish Gupta
Asked by Raghav Maheshwari: What kind of AI technology underlies Cortex and GenAI offerings?
p. 14
“Cortex is a knowledge engineering platform which is meant for developing agentic workflows with all the security, enterprise security, scalability, meant for life sciences.”
Manish Gupta, page 14 of the filed PDF · View the filing
Management said FY27 is about scaling FY26 initiatives rather than doing something new, citing Tectonic, GenAI-led wins, and the deferred $10 million deal converting to revenue.
Answered by Manish Gupta
Asked by Raghav Maheshwari: What are the growth drivers for FY27 and what will the company do differently?
p. 15
“FY27 is going to be more a year of scaling what we did in FY26.”
Manish Gupta, page 15 of the filed PDF · View the filing
Management said the biotech and smaller segment is an attractive area of expansion, while generics contribute some revenue but are a lower priority than innovator pharma.
Answered by Manish Gupta
Asked by Lakshminarayanan: Does Indegene serve generic and small/mid-sized pharma companies given the high revenue-per-employee model?
p. 16
“So, the whole biotech, and smaller segment, is attractive segment for us and we believe we will scale over there.”
Manish Gupta, page 16 of the filed PDF · View the filing
Management stated organic constant currency growth was 12% year-on-year and slightly over 3% quarter-on-quarter.
Answered by Suhas Prabhu
Asked by Yash Mehta: What was organic constant currency growth in Q4 FY26?
p. 16
“Constant currency terms year-on-year growth has been 12% organic and a little north of 3% QoQ.”
Suhas Prabhu, page 16 of the filed PDF · View the filing
Management said BioPharm integration was completed ahead of schedule and G&A synergies would show up first, with other synergies phasing in through FY27.
Answered by Suhas Prabhu
Asked by Yash Mehta: How will margins evolve in FY27 given BioPharm integration?
p. 16
“This completion of the transition would be adding to basically synergies on the G&A side.”
Suhas Prabhu, page 16 of the filed PDF · View the filing
Risks flagged
Delay in a large customer's decision-making due to an anticipated breakthrough not materializing on schedule
p. 4
“There was a bit of a hold due to a delay in a highly anticipated breakthrough as we continue to invest in the relationship.”
Manish Gupta, page 4 of the filed PDF · View the filing
Currency volatility affecting reported EBITDA via forward contracts
p. 9
“The high volatility in exchange rates, especially the depreciating INR against USD towards the closing days of the quarter has resulted in an incremental charge of ₹241 million in Q4 on the unexpired forward contracts.”
Suhas Prabhu, page 9 of the filed PDF · View the filing
US class action lawsuit alleging breach of the Telephone Consumer Protection Act requiring a settlement provision
p. 9
“Further, we have provided ₹203 million towards the estimated cost of settling the U.S. class action lawsuit filed in 2020 alleging breach of TCPA.”
Suhas Prabhu, page 9 of the filed PDF · View the filing
Lower interest income due to lower yields and higher amortization from recent acquisitions
p. 9
“We had a lower interest income due to lower yields and a higher amortization, as was mentioned in our Q3 earnings effective the acquisitions that we concluded in the recent past.”
Suhas Prabhu, page 9 of the filed PDF · View the filing
Margin impact from continued investments in talent and go-to-market
p. 11
“Further, you will also recollect the investments that we made, resulting in 150 basis points impact on our EBITDA margins, that we mentioned 2 quarters ago.”
Suhas Prabhu, page 11 of the filed PDF · View the filing
Uncertainty over long-term reliability of LLMs for regulated, operating-grade work, including a recent FDA warning letter concerning AI-generated content
p. 14
“There has been an FDA call out to one of the companies in just last 2 weeks a warning letter that looks AI generated.”
Manish Gupta, page 14 of the filed PDF · View the filing
Macro and regulatory uncertainty affecting the pharma industry entering FY26
p. 11
“The 3 concerns that warranted caution a year ago- new U.S. administrative uncertainty, regulatory policy overhang and macro volatility have largely been resolved.”
Manish Gupta, page 11 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.